Literature DB >> 31834934

von Willebrand factor and factor VIII levels after desmopressin are associated with bleeding phenotype in type 1 VWD.

Ferdows Atiq1, Lisette M Schütte1, Agnes E M Looijen1, Johan Boender1, Marjon H Cnossen2, Jeroen Eikenboom3,4, Moniek P M de Maat1, Marieke J H A Kruip1, Frank W G Leebeek1.   

Abstract

The bleeding phenotype of patients with type 1 von Willebrand disease (VWD) is very heterogeneous. We hypothesized that this heterogeneity may partly be explained by variability in response of von Willebrand factor (VWF) and factor VIII (FVIII) levels to stress during hemostatic challenges. We therefore investigated whether VWF and FVIII levels after administration of desmopressin, which mimic in vivo hemostatic response during hemostatic challenges, explain the heterogeneity in bleeding phenotype of patients with type 1 VWD. We performed a retrospective cohort study in 122 patients with type 1 VWD. All patients received a test dose of desmopressin shortly after diagnosis. Patients' mean age was 47 ± 14 years, and the mean Tosetto bleeding score was 10 ± 7. Higher FVIII activity during the complete time course after desmopressin administration (1, 3, and 5-6 hours), and higher VWF and FVIII levels combined at 3 hours after desmopressin administration, were associated with a lower bleeding score: β = -0.9 (-1.7; -0.1) and β = -1.2 (-1.9; -0.5), respectively, adjusted for age, sex, body mass index (BMI), and comorbidities. Patients with FVIII activity in the highest quartile 3 hours after desmopressin administration had a much lower bleeding score compared with patients in the other 3 quartiles (β = -5.1 [-8.2; -2.0]) and also had a lower chance of an abnormal bleeding score (odds ratio = 0.2 [0.1-0.5]), both adjusted for age, sex, BMI, and comorbidities. In conclusion, VWF and FVIII levels after desmopressin administration, which mimic hemostatic response to hemostatic challenges, are associated with the bleeding phenotype of patients with type 1 VWD. This may partly explain the variability in bleeding phenotype of these patients.
© 2019 by The American Society of Hematology.

Entities:  

Year:  2019        PMID: 31834934      PMCID: PMC6929395          DOI: 10.1182/bloodadvances.2019000863

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  32 in total

1.  Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels.

Authors:  Michelle Lavin; Sonia Aguila; Sonja Schneppenheim; Niall Dalton; Kenneth L Jones; Jamie M O'Sullivan; Niamh M O'Connell; Kevin Ryan; Barry White; Mary Byrne; Marie Rafferty; Mairead M Doyle; Margaret Nolan; Roger J S Preston; Ulrich Budde; Paula James; Jorge Di Paola; James S O'Donnell
Journal:  Blood       Date:  2017-09-15       Impact factor: 22.113

2.  The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease.

Authors:  Augusto B Federici; Paolo Bucciarelli; Giancarlo Castaman; Maria G Mazzucconi; Massimo Morfini; Angiola Rocino; Mario Schiavoni; Flora Peyvandi; Francesco Rodeghiero; Pier Mannuccio Mannucci
Journal:  Blood       Date:  2014-04-30       Impact factor: 22.113

3.  Clinically relevant differences between assays for von Willebrand factor activity.

Authors:  J Boender; J Eikenboom; J G van der Bom; K Meijer; J de Meris; K Fijnvandraat; M H Cnossen; B A P Laros-van Gorkom; W L van Heerde; E P Mauser-Bunschoten; M P M de Maat; F W G Leebeek
Journal:  J Thromb Haemost       Date:  2018-11-20       Impact factor: 5.824

4.  Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease.

Authors:  Eva M de Wee; Yvonne V Sanders; Eveline P Mauser-Bunschoten; Johanna G van der Bom; Manon E L Degenaar-Dujardin; Jeroen Eikenboom; Arja de Goede-Bolder; Britta A P Laros-van Gorkom; Karina Meijer; Karly Hamulyák; Marten R Nijziel; Karin Fijnvandraat; Frank W G Leebeek
Journal:  Thromb Haemost       Date:  2012-08-23       Impact factor: 5.249

5.  Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD.

Authors:  Giancarlo Castaman; Stefan Lethagen; Augusto B Federici; Alberto Tosetto; Anne Goodeve; Ulrich Budde; Javier Batlle; Dominique Meyer; Claudine Mazurier; Edith Fressinaud; Jenny Goudemand; Jeroen Eikenboom; Reinhard Schneppenheim; Jorgen Ingerslev; Zdena Vorlova; David Habart; Lars Holmberg; John Pasi; Frank Hill; Ian Peake; Francesco Rodeghiero
Journal:  Blood       Date:  2008-01-29       Impact factor: 22.113

6.  Significant gynecological bleeding in women with low von Willebrand factor levels.

Authors:  Michelle Lavin; Sonia Aguila; Niall Dalton; Margaret Nolan; Mary Byrne; Kevin Ryan; Barry White; Niamh M O'Connell; Jamie M O'Sullivan; Jorge Di Paola; Paula D James; James S O'Donnell
Journal:  Blood Adv       Date:  2018-07-24

Review 7.  von Willebrand factor and inflammation.

Authors:  C Kawecki; P J Lenting; C V Denis
Journal:  J Thromb Haemost       Date:  2017-07       Impact factor: 5.824

8.  von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease.

Authors:  Yvonne V Sanders; Dafna Groeneveld; Karina Meijer; Karin Fijnvandraat; Marjon H Cnossen; Johanna G van der Bom; M Coppens; Joke de Meris; Britta A P Laros-van Gorkom; Eveline P Mauser-Bunschoten; Frank W G Leebeek; Jeroen Eikenboom
Journal:  Blood       Date:  2015-02-11       Impact factor: 22.113

9.  Long-term impact of joint bleeds in von Willebrand disease: a nested case-control study.

Authors:  Karin P M van Galen; Piet de Kleijn; Wouter Foppen; Jeroen Eikenboom; Karina Meijer; Roger E G Schutgens; Kathelijn Fischer; Marjon H Cnossen; Joke de Meris; Karin Fijnvandraat; Johanna G van der Bom; Britta A P Laros-van Gorkom; Frank W G Leebeek; Eveline P Mauser-Bunschoten
Journal:  Haematologica       Date:  2017-06-01       Impact factor: 9.941

Review 10.  How I manage severe von Willebrand disease.

Authors:  Frank W G Leebeek; Ferdows Atiq
Journal:  Br J Haematol       Date:  2019-09-09       Impact factor: 6.998

View more
  4 in total

1.  The spectrum and severity of bleeding in adolescents with low von Willebrand factor-associated heavy menstrual bleeding.

Authors:  Lakshmi Srivaths; Charles G Minard; Sarah H O'Brien; Allison P Wheeler; Eric Mullins; Mukta Sharma; Robert Sidonio; Shilpa Jain; Ayesha Zia; Margaret V Ragni; Roshni Kulkarni; Jennifer E Dietrich; Peter A Kouides
Journal:  Blood Adv       Date:  2020-07-14

2.  Major differences in clinical presentation, diagnosis and management of men and women with autosomal inherited bleeding disorders.

Authors:  F Atiq; J L Saes; M C Punt; K P M van Galen; R E G Schutgens; K Meijer; M H Cnossen; B A P Laros-Van Gorkom; M Peters; L Nieuwenhuizen; M J H A Kruip; J de Meris; J G van der Bom; F J M van der Meer; K Fijnvandraat; I C Kruis; W L van Heerde; H C J Eikenboom; Frank W G Leebeek; S E M Schols
Journal:  EClinicalMedicine       Date:  2021-01-29

3.  Platelet degranulation and bleeding phenotype in a large cohort of Von Willebrand disease patients.

Authors:  Maurice Swinkels; Ferdows Atiq; Petra E Bürgisser; Iris van Moort; Karina Meijer; Jeroen Eikenboom; Karin Fijnvandraat; Karin P M van Galen; Joke de Meris; Saskia E M Schols; Johanna G van der Bom; Marjon H Cnossen; Jan Voorberg; Frank W G Leebeek; Ruben Bierings; A J Gerard Jansen
Journal:  Br J Haematol       Date:  2022-03-22       Impact factor: 8.615

4.  Von Willebrand Factor Multimer Densitometric Analysis: Validation of the Clinical Accuracy and Clinical Implications in Von Willebrand Disease.

Authors:  Johan Boender; Ferdows Atiq; Marjon H Cnossen; Johanna G van der Bom; Karin Fijnvandraat; Joke de Meris; Moniek P M de Maat; Karin P M van Galen; Britta A P Laros-van Gorkom; Karina Meijer; Jeroen Eikenboom; Frank W G Leebeek
Journal:  Hemasphere       Date:  2021-02-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.